Pet Financial News
Gallant Therapeutics Raises Over $15 Million in Series A Funding to Advance Pipeline of “Off-the-Shelf” Stem Cell Therapies for Pets
Leading Investors BOLD Capital, Digitalis Ventures, and Hill Creek Partners drive monetary milestone Financing to expedite conditional FDA approval of lead candidate and derisk...
Pet Financial News
[Latest] Pet Cancer Therapeutics Market Size Will Attain USD 15 Billion by 2030 Rising at 7% CAGR
Rise within the unmet medical wants and rising potential of pet most cancers treating medicine will open new development alternatives for the worldwide pet...
Pet Financial News
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
BOSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology firm dedicated to extra successfully treating most cancers utilizing...
- Advertisement -
Dog News
International Canine Flu Therapeutics Industry suggests it would attain US$ 3.06 Billion by 2033, buoyed by a 4.1% CAGR | FMI
Canine Flu Therapeutics Industry
The global canine flu therapeutics industry is anticipated to...
Pet Financial News
TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology firm dedicated to extra successfully treating most cancers utilizing...
Pet Financial News
TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Examine with Lead Therapeutic Candidate, TTX-MC138
Evidence of Drug Accumulation in Metastatic LesionsBOSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology firm dedicated to...
- Advertisement -
Pet Financial News
TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138
Further Supports TTX-MC138 Application in Brain CancerBOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology firm dedicated to...
-Advertisement-
Must read
-Advertisement-